These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 24342774)

  • 1. Social interaction and social withdrawal in rodents as readouts for investigating the negative symptoms of schizophrenia.
    Wilson CA; Koenig JI
    Eur Neuropsychopharmacol; 2014 May; 24(5):759-73. PubMed ID: 24342774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: a translational link to humans.
    Neill JC; Harte MK; Haddad PM; Lydall ES; Dwyer DM
    Eur Neuropsychopharmacol; 2014 May; 24(5):822-35. PubMed ID: 24287012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment.
    Millan MJ; Fone K; Steckler T; Horan WP
    Eur Neuropsychopharmacol; 2014 May; 24(5):645-92. PubMed ID: 24820238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Behavioral phenotypes for negative symptoms in animal models of schizophrenia.
    Miyamoto Y; Nitta A
    J Pharmacol Sci; 2014; 126(4):310-20. PubMed ID: 25409784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PCP-induced deficits in murine nest building activity: employment of an ethological rodent behavior to mimic negative-like symptoms of schizophrenia.
    Pedersen CS; Sørensen DB; Parachikova AI; Plath N
    Behav Brain Res; 2014 Oct; 273():63-72. PubMed ID: 25064467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of rodent models in the discovery of new treatments for schizophrenia: updating our strategy.
    Moore H
    Schizophr Bull; 2010 Nov; 36(6):1066-72. PubMed ID: 20870929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pick Your Model Wisely: Understanding the Negative Symptoms of Schizophrenia in Rodent Models.
    Yohn SE; Conn PJ
    ACS Chem Neurosci; 2019 Jan; 10(1):33-35. PubMed ID: 30346132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology.
    Neill JC; Grayson B; Kiss B; Gyertyán I; Ferguson P; Adham N
    Eur Neuropsychopharmacol; 2016 Jan; 26(1):3-14. PubMed ID: 26655189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative contribution of antipsychotics, negative symptoms and executive functions to social functioning in stable schizophrenia.
    Rocca P; Montemagni C; Castagna F; Giugiario M; Scalese M; Bogetto F
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):373-9. PubMed ID: 19211031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating negative-symptom-like behavioural changes in developmental models of schizophrenia.
    Moser P
    Eur Neuropsychopharmacol; 2014 May; 24(5):774-87. PubMed ID: 24332891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anhedonia, avolition, and anticipatory deficits: assessments in animals with relevance to the negative symptoms of schizophrenia.
    Barnes SA; Der-Avakian A; Markou A
    Eur Neuropsychopharmacol; 2014 May; 24(5):744-58. PubMed ID: 24183826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Animal models of schizophrenia.
    Jones CA; Watson DJ; Fone KC
    Br J Pharmacol; 2011 Oct; 164(4):1162-94. PubMed ID: 21449915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Negative Symptoms in Schizophrenia - an Overview].
    Klaus F; Kaiser S; Kirschner M
    Ther Umsch; 2018 Jun; 75(1):51-56. PubMed ID: 29909762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia.
    Carbon M; Correll CU
    CNS Spectr; 2014 Dec; 19 Suppl 1():38-52; quiz 35-7, 53. PubMed ID: 25403863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anxiety does not contribute to social withdrawal in the subchronic phencyclidine rat model of schizophrenia.
    Seillier A; Giuffrida A
    Behav Pharmacol; 2017 Oct; 28(7):512-520. PubMed ID: 28704273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors.
    Rodrigues da Silva N; Gomes FV; Sonego AB; Silva NRD; Guimarães FS
    Pharmacol Res; 2020 Jun; 156():104749. PubMed ID: 32151683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia.
    Goff DC; Coyle JT
    Am J Psychiatry; 2001 Sep; 158(9):1367-77. PubMed ID: 11532718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Negative symptoms in schizophrenia - overview and practical implications].
    Klaus F; Dorsaz O; Kaiser S
    Rev Med Suisse; 2018 Sep; 14(619):1660-1664. PubMed ID: 30230774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia.
    Grant PM; Huh GA; Perivoliotis D; Stolar NM; Beck AT
    Arch Gen Psychiatry; 2012 Feb; 69(2):121-7. PubMed ID: 21969420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Symptom domains of schizophrenia: the role of atypical antipsychotic agents.
    Burton S
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):6-19. PubMed ID: 17046984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.